TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
VRTX

Vertex Pharmaceuticals Inc

Healthcare · Biotechnology

516.30$ +0.6% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

Vertex Pharmaceuticals Inc (VRTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 3,334 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement VRTX
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
2,484 2,518 2,687 2,646 2,772 2,912 2,770 2,965 3,076 3,227 2,987 3,334 12,624
319 368 343 372 393 423 363 408 415 466 393 489 1,763
2,165 2,150 2,345 2,274 2,379 2,489 2,407 2,557 2,662 2,761 2,594 2,845 10,862
862 1,352 866 5,416 876 999 980 978 1,032 974 962 994 3,961
264 369 343 372 372 378 396 425 445 487 494 582 2,008
1,126 1,161 1,209 5,788 1,263 1,463 1,777 1,406 1,475 1,461 1,456 1,598 5,990
1,038 989 1,140 -3,515 1,116 1,026 630 1,151 1,186 1,300 1,138 1,247 4,872
11 11 10 9.9 7.5 2.8 3.0 3.7 3.3 3.3
1,179 1,148 1,279 -3,391 1,224 1,137 730 1,283 1,299 1,331 1,253 1,392 5,275
144 179 180 202 179 224 84 250 216 140 222 292 869
1,035 969 1,100 -3,594 1,045 913 646 1,033 1,083 1,191 1,031 1,100 4,405
1,232 1,217 1,343 -3,327 1,285 1,184 782 1,338 1,356 1,387 1,309 1,392 5,445

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?